WS
FHTX icon

Wedbush Securities’s Foghorn Therapeutics FHTX Stock Holding History

Wedbush Securities’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,634
Closed -$91K – 1073
2022
Q3 		$91K Buy
10,634
+442
+4% +$5.69K 0.01% 977
2022
Q2 		$139K Buy
+10,192
New +$132K 0.01% 978

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedbush Securities's FHTX Position: Q4 2022 in Review

Wedbush Securities sold out of Foghorn Therapeutics (FHTX) in Q4 2022, closing a stake of 10,634 shares — an estimated $91K sold.

Wedbush Securities first reported a position in FHTX in Q2 2022 and held it in 2 quarters. The position peaked at $139K in Q2 2022. 65 funds tracked by Wall St. Rank hold FHTX as of Q4 2022.

  • Wedbush Securities reported no remaining Foghorn Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Wedbush Securities sold 10,634 Foghorn Therapeutics shares in Q4 2022, an estimated $91K.
  • Wedbush Securities first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 2 quarters.
  • Wedbush Securities's Foghorn Therapeutics position peaked at $139K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2022.

Based on Wedbush Securities's 13F filing for Q4 2022, filed 31 Jan 2023.